Energy Storage Company Fluence Unveils SunFlex Energy Storage, its New Technology Platform for Solar PV
Fluence, an energy storage company owned by Siemens and The AES Corporation, announced its new technology platform, called SunFlex Energy Storage, that both improves and expands the capabilities of photovoltaic solar generation, already the fastest growing resource in the power sector. The company's newest energy storage technology platform enables solar facilities to sell up to 50 percent more clean energy per site, eliminates solar variability across the day – such as that caused by passing clouds – and expands the delivery of energy into the night, creating an on-demand solar resource.
“Solar and energy storage are the cheapest way to provide power in a number of markets today, and will reach economic parity in many more countries over the next five years,” said Stephen Coughlin, president and CEO of Fluence. "With Fluence’s SunFlex Energy Storage platform, customers can now deliver clean, abundant and low-cost solar energy on-demand, day or night.”
The growth in solar generation globally has been remarkable with the share of photovoltaics as a percentage of total generation doubling seven times between 2000 and 2015, according to Bloomberg New Energy Finance. However, the industry faces headwinds as increasing solar generation creates challenges for network operators, tasked with controlling system reliability, to manage the uncertainty caused by this variable resource. With Fluence's new technology platform, solar energy can now be delivered when it is needed most, not just when it is available. This innovation eliminates the need for back-up generation, such as peaking gas plants or reciprocating engines, to manage solar variability. This is especially critical on many microgrids and islands, where solar and storage combined are now the cheapest and most reliable form of energy available.
"The Fluence team originally developed energy storage solutions to replace inefficient or underutilized traditional power infrastructure assets such as power reserves, peaking, or wires," said John Zahurancik, COO of Fluence. “Today, as new power investment is flowing mainly into new solar generation, we have the chance to make this more efficient from the start. With our solution, we can get more solar energy from the same site and make the best use of our power networks.”
The Fluence SunFlex Energy Storage technology platform builds upon many of the industry-leading controls and architectural principles from Advancion and Siestorage, the company’s two technology platforms and the experience gained from working with leading solar developers such as sPower and AES Distributed Energy. The new platform captures the solar energy that otherwise would be lost during daily peak solar hours, and will increase the volume of energy delivered from a single site by up to 50 percent by allowing developers to add more solar panels without the cost of changing their interconnection. In addition, the new platform improves plant stability by smoothing and limiting the ramping of solar output, and in many areas, simplifies the interconnection process for combined solar and storage facilities. These improvements are only available from tailored energy storage solutions like Fluence’s SunFlex Energy Storage platform. In addition, energy storage can expand the capabilities of solar facilities by increasing the capacity factor of the plant and adding new sources of revenue from frequency regulation and other grid services.
With 10 years of experience and nearly 500 MW of energy storage projects deployed or awarded, Fluence is the leading energy storage technology and services company. Fluence combines the experience, talent and backing of industry giants and storage market leaders Siemens and AES to offer an unparalleled suite of energy storage capabilities. The Fluence team focuses on solving customers’ energy problems and prioritizing lasting partnerships over simply delivering products.
Learn more about Fluence, its team, and its new technology and service offerings at http://fluenceenergy.com.
Fluence, a Siemens and AES company, is a global energy storage technology solutions and services company that combines the agility of a technology company with the expertise, vision, and financial backing of two industry powerhouses. As the successor to industry pioneers AES Energy Storage and Siemens energy storage, Fluence’s goal is to create a more sustainable future by transforming the way we power our world. The company offers proven energy storage technology solutions designed to address the diverse needs and challenges of customers in a rapidly transforming energy landscape, providing design, delivery and integration in over 160 countries. Fluence works closely with customers throughout their journey and provides advisory, financing, and project lifecycle services. To date, Fluence’s teams have deployed or been awarded a market-leading 56 projects with a total capacity of 485 MW in 15 countries. To learn more, visit http://fluenceenergy.com/ and follow Fluence on Twitter at @FluenceEnergy.
Steven Goldman, 703-721-8673
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an